Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 8/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.39 |
| ▸ | FNTA | P49354 | 1/20 | 0.38 |
| ▸ | FNTB | P49356 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1375751 | 0.90 | HDAC8 (0.40) | S1PR1CYP2D6CYP3A4CYP2C9EPHX2 | |
| SCHEMBL2170259 | 0.90 | S1PR1 (0.42) | S1PR1CYP2D6CYP3A4CYP2C9EPHX2 | |
| SCHEMBL2170257 | 0.90 | S1PR1 (0.42) | S1PR1CYP2D6CYP3A4CYP2C9EPHX2 | |
| SCHEMBL1372949 | 0.90 | S1PR1 (0.42) | S1PR1CYP2D6CYP3A4CYP2C9EPHX2 | |
| SCHEMBL1373730 | 0.89 | F2 (0.46) | S1PR1CYP2D6CYP3A4CYP2C9LMNA | |
| SCHEMBL1372956 | 0.88 | MAPT (0.43) | S1PR1CYP2D6CYP3A4CYP2C9LMNA | |
| SCHEMBL2170199 | 0.88 | MAPT (0.43) | S1PR1CYP2D6CYP3A4CYP2C9LMNA | |
| SCHEMBL2356583 | 0.87 | S1PR1 (0.40) | S1PR1CYP2D6CYP3A4CYP2C9EPHX2 | |
| SCHEMBL1372171 | 0.87 | S1PR1 (0.40) | S1PR1CYP2D6CYP3A4CYP2C9EPHX2 | |
| SCHEMBL1371656 | 0.86 | S1PR1 (0.53) | S1PR1CYP2D6CYP3A4CYP2C9SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791102-B2 | Acetanilide sphingosine-1-phosphate receptor antagonists | EXELIXIS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | EXELIXIS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885CYP2D6 4804/4885CYP3A4 4784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.